Today, the robotic surgery is a modern revolutionary technology which is opened a qualitatively new stage in the surgery development in 21-st Century. High level of precision, reliability, functionality of robotic systems can extend the technical capabilities of the surgeons and improve quality of care. Contemporary colorectal surgery couldn’t exist without new technology and the quality of life after surgery directly depends on the quality of surgical care.

Breast cancer researches in recent years have shown that it is the most common form of cancer in women during pregnancy. According to the data from international statistical institutes, this form of cancer in women younger than 45 years account for 8% of all cases. The frequency of detection of breast cancer during pregnancy ranges from 1 in 10,000 pregnant women to 1 in 3,000 pregnancies.  The reason that a rare combination of breast cancer and pregnancy is no longer a rarity now, is the older age of childbearing, and that the cohort of patients expands to include those women with breast cancer who were diagnosed during one year after childbirth.

The article presents a review of clinical trials of treatment the triple negative breast cancer (TNBC). It considered the activity of existing target agents and chemotherapy. Described is not an ordinary case of the clinical course and treatment of TNBC.

The experience of adjuvant treatment of patients with gastrointestinal stromal tumors (GIST) demonstrated its high efficiency, allowing to increase disease-free survival by almost 2 times. Currently, low-risk patients after radical surgical treatment need dynamic observation, patients with moderate-risk recommended to receive adjuvant treatment with imatinib for 1 year and high risk patients – for 3 years. This article presents an overview of the most important prognostic factors, the analysis of which will allow clinical oncologist to stratify patients into risk groups more accurately and thus increase the effectiveness of the targeted therapy.

Prostate cancer is the most common form of cancer in men in Western countries and in some countries is in second place in the list of leading causes of cancer death in men. About 300 000 new cases of prostate cancer registered in Europe annually. This number increases to 670,000 cases worldwide.